The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Selecting the right treatment for relapsed diffuse large B-cell lymphoma
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses key considerations for selecting treatment in relapsed diffuse large B-cell lymphoma (DLBCL), including the role of CAR T-cell therapy, autologous stem cell transplantation, and bispecific antibodies based on relapse timing, patient fitness, and disease characteristics. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So my education session on relapsed diffuse large B-cell lymphoma highlights a number of things, primarily that we now have a huge treatment option for our patients. We’ve got a vast choice and it’s really about trying to select the right treatment for the right patient at the right time. And for lots of these options, they are now available in almost all hospital settings, obviously with the exception of CAR-T that has to be delivered in a CAR-T centre...
So my education session on relapsed diffuse large B-cell lymphoma highlights a number of things, primarily that we now have a huge treatment option for our patients. We’ve got a vast choice and it’s really about trying to select the right treatment for the right patient at the right time. And for lots of these options, they are now available in almost all hospital settings, obviously with the exception of CAR-T that has to be delivered in a CAR-T centre. So when we’re thinking about what the considerations are, a primary consideration is the timing from relapse. So for patients who relapse within 12 months of their first-line therapy, these are the patients who may be eligible for CAR-T treatment. Obviously, other considerations include disease kinetics to make sure that we have time for apheresis and awaiting for CAR-T manufacturing. But generally, for early relapsing patients, CAR-T would be the preferred choice. For later relapsing patients, if they are autologically fit, then we would consider high-dose chemotherapy and an autologous stem cell transplant. And for those patients who we can’t access either CAR-T or an autologous transplant, the options now include the availability of glofitamab and GemOx in a second-line setting for patients who are not fit for auto or not eligible for auto. And I spend some time thinking about these criteria and how we make patient selection. But glofitamab and GemOx is an option that can be used in many community hospitals, unlike CAR-T and autologous stem cell transplant, which has to be delivered either in a transplant centre or in a CAR-T centre. So I think that patient selection, fitness, disease kinetics, performance status, where the patient lives are all important factors as well as time from relapse.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
